We suggest that if MRPL42 expression could be therapeutically targeted through the inhibition of YY1 [67], then the size of MRPL42-overexpressing LUAD tumours could be reduced and the presence of lymph node metastases significantly diminished [47]. Here, MRPL42 is linked to neoplasm.